Vanessa D. Redecke

Vanessa D. Redecke, MD, PhD

Languages spoken: English, German

Academic Information

Departments Primary - Pathology

Academic Office Information

Vanessa.Redecke@path.utah.edu

Lab

Research Interests

  • Immunology
  • Innate Immunity
  • Inflammation
  • Signal Transduction
  • Infectious disease mechanisms (host-pathogen interaction)
  • Toll-Like Receptors
  • Anti-Inflammatory Drug Development
  • Autoimmune Diseases

Vanessa Redecke a Research Assistant Professor in the Haecker Lab in the Division of Microbiology & Immunology, where her research focuses on understanding innate immunity, host-pathogen interaction, inflammation and autoimmune diseases.

After completing her MD/PhD training in Germany, she pursued her postgraduate studies at the University of California, San Diego under the guidance of Eyal Raz, before joining the faculty at St Jude Children's Research Hospital in Memphis, TN, and since 2019, at the University of Utah.

Throughout her journey, she has always been fascinated by how environmental factors and pathogens impact immunity and the progression of diseases, laying the groundwork for her ongoing research.

HER CURRENT RESEARCH

  • Uncovering novel signaling molecules and mechanisms that govern pathogen recognition and physiological and pathological cell activation.
  • Developing small molecule inhibitors to combat inflammation and offer new treatment options to patients affected by inflammatory and autoimmune diseases.

HER ENTREPRENEURIAL EXPERIENCE

  • In addition to her academic pursuits, she co-founded Nanospot.ai. This company is built on an innovative AI-driven technology for rapid medical diagnostic tests designed for point-of-care and home use.

Ultimately, her goal is to translate fundamental immunological discoveries into healthcare solutions and to develop innovative therapies to alleviate inflammatory and autoimmune diseases.

For more information about her lab, her research, lab tips and tricks, University of Utah and life in Utah resources, check out the Haecker lab website at https://www.haeckerlab.org.

Education History

Postdoctoral Training University of California, San Diego School of Medicine
 Postdoctoral Researcher
Technical University Munich School of Medicine
 Resident
Residency Technical University Munich School of Medicine
 Resident
University of Lübeck Medical School
 PhD
Professional Medical University of Lübeck Medical School
 MD

Selected Publications

Journal Article

  1. Kuriakose J, Redecke V, Guy C, Zhou J, Wu R, Ippagunta SK, Tillman H, Walker PD, Vogel P, Hacker H (2019). Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis.LID - 10.1172/JCI125116 [doi]LID - 125116 [pii]. J Clin Invest, 130. (Read full article)
  2. Pollock JA, Sharma N, Ippagunta SK, Redecke V, Hacker H, Katzenellenbogen JA (2018). Triaryl Pyrazole Toll-Like Receptor Signaling Inhibitors: Structure-Activity Relationships Governing Pan- and Selective Signaling Inhibitors. ChemMedChem, 13(20), 2208-2216. (Read full article)
  3. Ippagunta SK, Pollock JA, Sharma N, Lin W, Chen T, Tawaratsumida K, High AA, Min J, Chen Y, Guy RK, Redecke V, Katzenellenbogen JA, Hacker H (2018). Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins.LID - eaaq1077 [pii]LID - 10.1126/scisignal.aaq1077 [doi]. Sci Signal, 11(543). (Read full article)
  4. Ippagunta SK, Gangwar R, Finkelstein D, Vogel P, Pelletier S, Gingras S, Redecke V, Hacker H (2016). Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1 function. Proc Natl Acad Sci U S A, 113(41), E6162-E6171. (Read full article)
  5. Redecke V, Chaturvedi V, Kuriakose J, Hacker H (2016). SHARPIN controls the development of regulatory T cells. Immunology, 148(2), 216-26. (Read full article)
  6. Tawaratsumida K, Phan V, Hrincius ER, High AA, Webby R, Redecke V, Hacker H (2014). Quantitative proteomic analysis of the influenza A virus nonstructural proteins NS1 and NS2 during natural cell infection identifies PACT as an NS1 target protein and antiviral host factor. J Virol, 88(16), 9038-48. (Read full article)
  7. Redecke V, Wu R, Zhou J, Finkelstein D, Chaturvedi V, High AA, Hacker H (2013). Hematopoietic progenitor cell lines with myeloid and lymphoid potential. Nat Methods, 10(8), 795-803. (Read full article)
  8. LeMessurier KS, Hacker H, Chi L, Tuomanen E, Redecke V (2013). Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog, 9(11), e1003727. (Read full article)
  9. Zhou J, Wu R, High AA, Slaughter CA, Finkelstein D, Rehg JE, Redecke V, Hacker H (2011). A20-binding inhibitor of NF-kappaB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein beta activation and protects from inflammatory disease. Proc Natl Acad Sci U S A, 108(44), E998-1006. (Read full article)
  10. Stempin CC, Chi L, Giraldo-Vela JP, High AA, Hacker H, Redecke V (2011). The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-kappaB activation. J Biol Chem, 286(43), 37147-57. (Read full article)
  11. LeMessurier K, Hacker H, Tuomanen E, Redecke V (2010). Inhibition of T cells provides protection against early invasive pneumococcal disease. Infect Immun, 78(12), 5287-94. (Read full article)
  12. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Hacker G, Mann M, Karin M (2006). Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature, 439(7073), 204-7. (Read full article)
  13. Schmidt R, Redecke V, Breitfeld Y, Wantia N, Miethke T, Massberg S, Fischel S, Neumann FJ, Schomig A, May AE (2006). EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture. Thromb Haemost, 95(1), 151-8. (Read full article)
  14. Hayashi T, Gong X, Rossetto C, Shen C, Takabayashi K, Redecke V, Spiegelberg H, Broide D, Raz E (2005). Induction and inhibition of the Th2 phenotype spread: implications for childhood asthma. J Immunol, 174(9), 5864-73. (Read full article)
  15. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, Lipford GB, Zenke M (2004). Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene, 331, 159-64. (Read full article)
  16. Redecke V, Hacker H, Datta SK, Fermin A, Pitha PM, Broide DH, Raz E (2004). Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol, 172(5), 2739-43. (Read full article)
  17. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E, Cottam HB (2003). Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A, 100(11), 6646-51. (Read full article)
  18. May AE, Redecke V, Gruner S, Schmidt R, Massberg S, Miethke T, Ryba B, Prazeres da Costa C, Schomig A, Neumann FJ (2003). Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, nonatherosclerotic mice. Arterioscler Thromb Vasc Biol, 23(5), 789-94. (Read full article)
  19. Datta SK, Redecke V, Prilliman KR, Takabayashi K, Corr M, Tallant T, DiDonato J, Dziarski R, Akira S, Schoenberger SP, Raz E (2003). A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol, 170(8), 4102-10. (Read full article)
  20. Prebeck S, Kirschning C, Durr S, da Costa C, Donath B, Brand K, Redecke V, Wagner H, Miethke T (2001). Predominant role of toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. J Immunol, 167(6), 3316-23. (Read full article)
  21. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A, 98(16), 9237-42. (Read full article)
  22. Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP, Wagner H, Lipford GB (2001). Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol, 166(8), 5000-7. (Read full article)
  23. Redecke V, Dalhoff K, Bohnet S, Braun J, Maass M (1998). Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Am J Respir Cell Mol Biol, 19(5), 721-7. (Read full article)

Review

  1. Horner AA, Redecke V, Raz E (2004). Toll-like receptor ligands: hygiene, atopy and therapeutic implications. [Review]. Curr Opin Allergy Clin Immunol, 4(6), 555-61.
  2. Hcker G, Redecke V, Hcker H (2002). Activation of the immune system by bacterial CpG-DNA. [Review]. Immunology, 105, 245-51.

Patent

  1. (2022). Remote image analysis for visually assessing agglutination of fluid samples. U.S. Patent No. US20230029423A1. Washington, D.C.:U.S. Patent and Trademark Office.
  2. (2021). Rapid assay for detection of SARS-CoV-2 antibodies. U.S. Patent No. US11467165B2. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Redecke V (2005). Methods of treating immunopathological disorders. U.S. Patent No. WO2005079419A2. Washington, D.C.:U.S. Patent and Trademark Office.